ALN TTRsc02

Drug Profile

ALN TTRsc02

Alternative Names: ALN-TTRsc02

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Heart failure therapies; Small interfering RNA
  • Mechanism of Action Prealbumin inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyloidosis

Most Recent Events

  • 02 Jan 2017 9209054: updated KDM, TT and AE
  • 19 Dec 2016 Efficacy and adverse events data from a phase I trial in Healthy volunteers released by Alnylam Pharmaceuticals
  • 09 Jun 2016 Phase-I clinical trials in Amyloidosis in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top